XML 52 R42.htm IDEA: XBRL DOCUMENT
v3.19.1

Collaborative Arrangements and Licensing Agreements, Biogen (Details) $ in Thousands | 1 Months Ended | 3 Months Ended |
--- | --- | --- | ---
Apr. 30, 2019 USD ($) | Mar. 31, 2019 USD ($) Drug | Jun. 30, 2018 USD ($) | Mar. 31, 2018 USD ($) | Dec. 31, 2018 USD ($)
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |
Revenue |  | $ 297,214 |  | $ 144,419 |
SPINRAZA Royalties [Member] |  |  |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |
Revenue |  | 59,711 |  | 41,081 |
R&D [Member] |  |  |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |
Revenue |  | $ 229,126 |  | 102,396 |
Biogen [Member] |  |  |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |
Number of additional drugs in clinical development to treat neurodegenerative diseases | Drug |  | 6 |  |  |
Cumulative payments received |  | $ 2,100,000 |  |  |
Revenue |  | 84,200 |  | $ 51,900 |
Deferred revenue |  | $ 556,400 |  |  | $ 580,900
Biogen [Member] | Revenue [Member] | Strategic Partner [Member] |  |  |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |
Concentration percentage |  | 28.00% |  | 36.00% |
Biogen [Member] | SPINRAZA Royalties [Member] |  |  |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |
Revenue |  | $ 59,700 |  | $ 41,100 |
Biogen [Member] | R&D [Member] |  |  |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |
Revenue |  | $ 24,500 |  | $ 10,800 |
2018 Strategic Neurology [Member] |  |  |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |
Upfront payment received |  |  | $ 1,000,000 |  |
2018 Strategic Neurology [Member] | Subsequent Event [Member] |  |  |  |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |  |  |  |
Milestone payment received | $ 7,500 |  |  |  |
Next prospective milestone | $ 10,000 |  |  |  |

X
- References No definition available. + Details
Name: | ions_CollaborativeArrangementAndLicensingAgreementAbstract
Namespace Prefix: | ions_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Cumulative amount of payments received under the collaboration agreement as of the end of the reporting period. + References No definition available. + Details
Name: | ions_CumulativePaymentsReceived
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The amount of milestone payments received during the period under the collaboration agreement. + References No definition available. + Details
Name: | ions_MilestonePaymentsReceived
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The next potential milestone payment to be earned under the collaboration agreement. + References No definition available. + Details
Name: | ions_NextPotentialMilestonePayment
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The number of additional drugs in clinical development to treat neurodegenerative diseases under the collaboration agreement. + References No definition available. + Details
Name: | ions_NumberOfAdditionalDrugsInClinicalDevelopmentToTreatNeurodegenerativeDiseases
Namespace Prefix: | ions_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition The total amount of the upfront payment received, including the purchase of shares of the Company's stock, under the collaboration agreement. + References No definition available. + Details
Name: | ions_UpfrontPaymentReceivedIncludingPurchaseOfStock
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=109250915&loc=d3e13531-108611 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109250915&loc=d3e13537-108611 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592 + Details
Name: | us-gaap_ConcentrationRiskPercentage1
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130532-203044 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045 + Details
Name: | us-gaap_ContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=ions_SPINRAZARoyaltiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ions_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementsAndLicensingAgreementsBiogenMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByBenchmarkAxis=ions_RevenueFromContractWithCustomerBenchmarkMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |